MOESM1 of Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes

Gilberto Velho, Stéphanie Ragot, Ray El Boustany, Pierre-Jean Saulnier, Mathilde Fraty, Kamel Mohammedi, Frédéric Fumeron, Louis Potier, Michel Marre, Samy Hadjadj, Ronan Roussel
2018 Figshare  
Additional file 1: Figure S1. Plasma copeptin by KDIGO eGFR categories and by UAC categories at baseline. Table S1. Clinical characteristics at baseline by tertiles of plasma copeptin. Table S2. Risk of individual cardiovascular outcomes during follow-up by tertiles of plasma copeptin at baseline—DIABHYCAR and SURDIAGENE pooled data. Table S3. Rapid kidney function decline during follow-up by tertiles of plasma copeptin at baseline. Table S4. SURGENE cohort—Kidney outcome during the follow-up
more » ... tertiles of plasma copeptin at baseline. Table S5. Cardiovascular events during follow-up by tertiles of plasma copeptin at baseline—DIABHYCAR and SURDIAGENE pooled data. Additional information. Centers and staff involved in SURDIAGENE recruitment and adjudication.
doi:10.6084/m9.figshare.6916454 fatcat:ttc3l3hlpvfmpn273hea5epee4